The molecule isn't the work. The dose is the work.
Pick up two copper peptide serums. Both list Copper Tripeptide-1 in the INCI. One costs nine euros, the other costs fifty-eight euros. The molecule on paper is the same. Why the price gap?
The answer is almost always concentration.
The studied range
Published in-vitro work on Copper Tripeptide-1 sits in the range 0.1–2.0%. Below 0.1% the molecule has trouble out-competing other ingredients for receptor binding at the skin surface. Above 2.0% the dose stops producing additional in-vitro effect (and starts adding cost without benefit).
That means a copper peptide formulated at 0.05% — below the studied bracket — is selling you the peptide name, not the work. It will sit in your bathroom for six months, finish empty, and you will conclude that copper peptides “didn't work for you.”
What 1.0% looks like in a 30 ml bottle
1.0% of 30 ml is 300 mg of active peptide per bottle. At the standard 3–5 drop application, twice daily, a bottle lasts roughly 8–10 weeks. You finish it. You feel a difference. Or you don't — because the peptide isn't the right one for your skin — but at least you got a fair test.
The same logic applies to every peptide we ship
Matrixyl 3000 has data at 3–10%. We formulate at 10%. Argireline has data at 5–10%. We formulate at 10%. Snap-8 at 3–5%, we formulate at 5%. The principle is the same: top of the bracket, on the front of the bottle.
What we do not believe
We do not believe in the “less is more” framing where 0.3% of an active is sold as a delicate formulation. Some actives are dose-sensitive at the irritation threshold (retinol, AHAs). Cosmetic signal peptides are not. There is no skin discomfort tradeoff for formulating at the top of the bracket.
Read it on the bottle.
That is the only check that matters. If the brand will print the percentage on the front, the rest of the conversation is easy.